Hospital use systemic antifungal drugs

Research output: Contribution to journalResearch articleContributedpeer-review


  • Katja de With - , University Medical Center Freiburg (Author)
  • Michaela Steib-Bauert - , University of Freiburg (Author)
  • Holger Knoth - , University Medicine (Faculty of Medicine and University Hospital), Pharmacy (Author)
  • Frank Dörje - , Friedrich-Alexander University Erlangen-Nürnberg (Author)
  • Egid Strehl - , University of Freiburg (Author)
  • Ulrich Rothe - , University of Regensburg (Author)
  • Ludwig Maier - , Ulm University (Author)
  • Winfried V. Kern - , University of Freiburg (Author)


Background: Sales data indicate a major increase in the prescription of antifungal drugs in the last two decades. Many new agents for systemic use that only recently have become available are likely to be prescribed intensively in acute care hospitals. Sales data do not adequately describe the developments of drug use density. Given the concerns about the potential emergence of antifungal drug resistance, data on drug use density, however, may be valuable and are needed for analyses of the relationship between drug use and antifungal resistance. Methods: Hospital pharmacy records for the years 2001 to 2003 were evaluated, and the number of prescribed daily doses (PDD, defined according to locally used doses) per 100 patient days were calculated to compare systemic antifungal drug use density in different medical and surgical service areas between five state university hospitals. Results: The 3-year averages in recent antifungal drug use for the five hospitals ranged between 8.6 and 29.3 PDD/ 100 patient days in the medical services (including subspecialties and intensive care), and between 1.1 and 4.0 PDD/ 100 patient days in the surgical services, respectively. In all five hospitals, systemic antifungal drug use was higher in the hematology-oncology service areas (mean, 48.4, range, 24 to 10 1 PDD/100 patient days, data for the year 2003) than in the medical intensive care units (mean, 18.3, range, 10 to 33 PDD/100) or in the surgical intensive care units (mean, 10.7, range, 6 to 18 PDD/100). Fluconazole was the most prescribed antifungal drug in all areas. In 2003, amphotericin B consumption had declined to 3 PDD/100 in the hernatology-oncology areas while voriconazole use had increased to 10 PDD/100 in 2003. Conclusion: Hematology-oncology services are intense antifungal drug prescribing areas. Fluconazole and other azol antifungal drugs are the most prescribed drugs in all patient care areas while amphotericin B use has considerably decreased. The data may be useful as a benchmark for focused interventions to improve prescribing quality.


Original languageEnglish
Article number1
JournalBMC Clinical Pharmacology
Publication statusPublished - 10 Feb 2005

External IDs

PubMed 15703083
ORCID /0000-0001-9473-3018/work/148606236


ASJC Scopus subject areas